AstraZeneca Divests Rights to Two Cardiovascular Drugs for $400 Million


2020-10-31 03:01:17 BioSpace


Ruud Dobber, executive vice president of AstraZeneca’s BioPharmaceuticals Business Unit, pictured above. Photo courtesy of AstraZeneca.  AstraZeneca is divesting two cardiovascular drugs to Germany’s Cheplapharm Arzneimittel GmbH for $400 million, which will allow the UK pharma giant to reinvest in its main therapy areas. This morning, AstraZeneca said it agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) to Cheplapharm. The drugs, approved for treatment of heart failure and hypertension, respectively, are commercially available in approximately 70 countries across the globe. For Cheplapharm, the deal piggybacks onto a 2018 agreement to acquire the European rights to Atacand. The agreement announced today will allow that company to expand the reach of the cardiovascular drug into additional countries across the globe. Atacand (candesartan cilexetil) is a selective, AT1 subtype angiotensin II receptor antagonist is indicated for the management of hypertension in adults and children/adolescents, as well as HF in adults. Atacand Plus is indicated for the management of hypertension when candesartan or hydrochlorothiazide monotherapy is not sufficiently effective. Under terms of the agreement, AstraZeneca will continue to manufacture and supply Atacand and Atacand plus and will continue to commercialize the medicine during a three-year transition period. Of the $400 million payment for the two drugs, Cheplapharm Arzneimittel GmbH will pay AstraZeneca $250 million when the deal is completed in the fourth quarter of this year, and the remaining $150 million will be paid in the first half of 2021. Ruud Dobber, executive vice president of AstraZeneca’s BioPharmaceuticals Business Unit, said the decision to sell the rights to the drugs is part of the company’s strategy to “manage” its mature medications in order to use proceeds from the sale for reinvestment in the company’s core therapies. The divestment of the drugs will not impact AstraZeneca’s financial guidance for 2020, the company noted. Last year, Atacand and Atacand Plus generated sales of $148 million and profit before tax of $89 million in those 70 countries, AstraZeneca said. Last year, the two companies struck a separate deal for an acid reflux treatment. Cheplapharm acquired the commercial rights to Losec (omeprazole) and associated brands containing omeprazole marketed by AstraZeneca or its collaborators under the Acimax, Antra, Mepral, Mopral, Omepral and Zoltum brand names. Losec is a proton pump inhibitor discovered and developed by AstraZeneca, which helps to reduce the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers. At the time of the Losec deal, Dobber said the decision to divest that asset also centered on the management of mature drug assets.
上图为阿斯利康生物制药事业部执行副总裁吕德·多伯。照片由阿斯利康提供。 阿斯利康将以4亿美元的价格将两种心血管药物出售给德国Cheplapharm Arzneimittel GmbH,这将使这家英国制药巨头能够在其主要治疗领域进行再投资。 今天上午,阿斯利康表示,同意将商业权利出售给Atacand(坎地沙坦酯)和Atacand Plus(坎地沙坦酯和氢氯噻嗪的固定剂量组合)给Cheplapharm。这些药物分别被批准用于治疗心力衰竭和高血压,在全球约70个国家有售。对Cheplapharm来说,这笔交易是在2018年达成的收购Atacand欧洲经营权协议的基础上达成的。今天宣布的协议将允许该公司将心血管药物的影响范围扩大到全球其他国家。 阿他康(坎地沙坦酯)是一种选择性AT1亚型血管紧张素II受体拮抗剂,用于治疗成人和儿童/青少年高血压,以及成人心力衰竭。当坎地沙坦或氢氯噻嗪单药治疗效果不佳时,阿塔康加治疗方案可用于高血压的治疗。 根据协议条款,阿斯利康将继续生产和供应Atacand和Atacand plus,并将在三年过渡期内继续将该药物商业化。在这两种药物的4亿美元付款中,Cheplapharm Arzneimittel GmbH将在今年第四季度交易完成时向阿斯利康支付2.5亿美元,其余1.5亿美元将在2021年上半年支付。 阿斯利康生物制药业务部门执行副总裁吕德·多伯表示,出售这些药物权利的决定是公司“管理”其成熟药物战略的一部分,以便将出售所得用于对公司核心疗法的再投资。阿斯利康指出,剥离这些药物不会影响阿斯利康2020年的财务指导。 阿斯利康称,去年,Atacand和Atacand Plus在这70个国家的销售额为1.48亿美元,税前利润为8900万美元。 去年,两家公司就酸回流治疗达成了单独的协议。Cheplapharm获得了Losec(奥美拉唑)和由阿斯利康或其合作者以Acimax,Antra,Mepral,Mopral,Omepral和Zoltum品牌名销售的含有奥美拉唑的相关品牌的商业权利。洛赛克是阿斯利康发现和开发的质子泵抑制剂,有助于减少胃肠反流条件和溃疡患者胃产生的酸量。在Losec交易时,Dobber表示,剥离那笔资产的决定也围绕着成熟药品资产的管理。